<DOC>
	<DOCNO>NCT01904682</DOCNO>
	<brief_summary>The study enroll low risk MDS patient need red blood cell transfusion refractory use erythropoiesis-stimulating agent . The purpose study determine whether oral rigosertib treatment result hematological improvement accord 2006 International Working Group criteria patient . The study also record side effect may occur study .</brief_summary>
	<brief_title>Oral Rigosertib Low Risk MDS Patients Refractory ESAs</brief_title>
	<detailed_description>This Phase II , single-arm , multicenter study ( approximately 15 center ) . Approximately 40 transfusion-dependent patient Low- Int-1 risk Myelodysplastic Syndrome ( MDS ) International Prognostic Scoring System ( IPSS ) enrol treated oral rigosertib administer twice daily 21 consecutive day 21-day cycle ( continuous regimen ) order obtain least 35 evaluable patient treat least 8 week . Patients take 560 mg rigosertib ( two 280 mg capsule ) morning 280 mg ( one 280 mg capsule ) afternoon , fast condition . All patient intermittent regimen time Amendment 2 Protocol switch continuous regimen , include patient reduced dos .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>Diagnosis MDS accord World Health Organization ( WHO ) criterion ( Appendix 2 ) FrenchAmericanBritish ( FAB ) classification must confirm bone marrow ( BM ) aspirate and/or biopsy within 6 week prior Screening . Myelodysplastic syndrome ( MDS ) classify Low risk Int1 risk , accord International Prognostic Scoring System ( IPSS ) classification ; addition , patient never classify Int2 Highrisk since MDS diagnose ; Transfusion dependency define transfusion least 4 unit Red blood cell ( RBC ) within 56 day Screening ( pretransfusion Hgb value value must ≤ 9 g/dL take account ) . Refractory 8 12week course Erythropoiesisstimulating agent ( ESA ) administer within past 2 year enrollment , erythropoietin ( EPO ) level ˃ 500 mU/mL ESA least 8 week Screening . Off treatment MDS ( azacitidine , decitabine , lenalidomide , chemotherapy , immunotherapy ) least 2 week prior Screening . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 2 . Willing adhere prohibition restriction specify protocol . The patient must sign informed consent form ( ICF ) indicate s/he understands purpose , procedure require , study willing participate . Ongoing clinically significant anemia due factor iron , vitamin B12 , folate deficiency , autoimmune hereditary hemolysis , gastrointestinal ( GI ) bleeding . Serum ferritin &lt; 50 ng/mL . Hypoplastic MDS ( cellularity &lt; 10 % ) Any active malignancy within past year , except basal cell squamous cell skin cancer carcinoma situ cervix breast . Uncontrolled intercurrent illness include , limited , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia . Active infection adequately respond appropriate therapy . Total bilirubin ≥ 2.0 mg/dL relate hemolysis Gilbert 's disease . Alanine transaminase ( ALT ) aspartate transaminase ( AST ) ≥ 2.5 x upper limit normal ( ULN ) . Serum creatinine ≥ 2.0 mg/dL . Ascites require active medical management include paracentesis . Hyponatremia ( define serum sodium value &lt; 130 mEq/L ) . Female patient pregnant lactate . Patients childbearing potential unwilling follow strict contraception requirement . Female patient reproductive potential negative blood urine pregnancy test Screening . Major surgery without full recovery major surgery within 3 week Screening . Uncontrolled hypertension ( define systolic pressure ≥ 160 mmHg and/or diastolic pressure ≥ 110 mmHg ) . New onset seizure ( within 3 month prior first dose rigosertib ) poorly control seizure . Any concurrent investigational agent chemotherapy , radiotherapy , immunotherapy . Chronic use ( ˃ 2 week ) corticosteroid ( ˃ 10 mg/24 hr equivalent prednisone ) within 4 week Screening . Investigational therapy within 4 week Screening . Allergy local anaesthetic . Psychiatric illness social situation would limit patient 's ability tolerate and/or comply study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Erythrocyte transfusion</keyword>
	<keyword>Erythropoiesis-stimulating agent</keyword>
	<keyword>International Prognostic Scoring System</keyword>
</DOC>